Affimed Earnings Call Transcripts
Fiscal Year 2025
-
The session highlighted strong clinical progress for AFM24 and AFM28, with both programs showing promising efficacy and safety profiles in difficult-to-treat cancers. Strategic prioritization is ongoing, with investor and partner input guiding future development and financing decisions.
Fiscal Year 2024
-
AFM24 plus atezolizumab showed robust efficacy and safety in heavily pretreated NSCLC, with higher drug exposure linked to improved outcomes. A new 720 mg cohort will open in 2025 to confirm enhanced response rates and PFS, supporting further clinical development.
-
Clinical programs for AFM24, AFM28, and acimtamig advanced, with key data updates at ASH 2024 and a December call for AFM24. Cash runway extends into Q4 2025, with reduced expenses and net loss. Strategic focus includes broadening partnerships and financial stability.
-
Three NK cell engager programs show strong efficacy and durability in refractory cancers, with AFM13 achieving high response rates in Hodgkin lymphoma and AFM24 demonstrating durable responses in NSCLC. Regulatory and commercial strategies are advancing, with pivotal data expected later this year.
-
Clinical programs in NSCLC, Hodgkin lymphoma, and AML showed strong early efficacy and safety, with financials reflecting reduced expenses and improved net loss. Cash runway extends into H2 2025, with key data readouts and strategic decisions expected in the next 12–24 months.
-
Clinical validation was achieved across all programs, with strong efficacy signals in difficult-to-treat cancers and improved financial efficiency. Durable responses were observed in lung cancer and lymphoma, and the company is well-positioned for further data readouts in 2024.
-
Combination of AFM24 and atezolizumab showed promising efficacy and manageable safety in heavily pretreated EGFR wild-type and mutant NSCLC patients, including those refractory to prior immunotherapy. Fast Track designation was granted, and further clinical development is planned.